Lb Pharmaceuticals (LBRX) Liabilities and Shareholders Equity (2024 - 2026)

Lb Pharmaceuticals' Liabilities and Shareholders Equity history runs 3 years deep, the most recent figure standing at $393.5 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity changed N/A year-over-year to $393.5 million; the TTM figure through Mar 2026 stood at $1.0 billion (changed N/A YoY), while the FY2025 annual figure was $312.9 million, up 833.18% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $393.5 million, up from $312.9 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $393.5 million in Q1 2026, with the low at $33.5 million in Q4 2024.
• The 3-year median for Liabilities and Shareholders Equity is $316.8 million (2025), against an average of $265.2 million.
• Peak annual rise in Liabilities and Shareholders Equity reached 833.18% in 2025, while the deepest fall reached 833.18% in 2025.
• Lb Pharmaceuticals' Liabilities and Shareholders Equity stood at $33.5 million in 2024, then jumped by 833.18% to $312.9 million in 2025, then advanced by 25.74% to $393.5 million in 2026.
• Business Quant data shows LBRX's Liabilities and Shareholders Equity at $393.5 million in Q1 2026, $312.9 million in Q4 2025, and $320.7 million in Q3 2025.